Neumora Therapeutics, Inc.
NMRA
$1.20
-$0.05-4.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -20.80% | -17.06% | -3.91% | 11.50% | 19.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.04% | -20.50% | -10.36% | -4.01% | 14.59% |
| Operating Income | 22.04% | 20.50% | 10.36% | 4.01% | -14.59% |
| Income Before Tax | 15.56% | 13.75% | 2.80% | 19.47% | 7.99% |
| Income Tax Expenses | -83.61% | -80.57% | -26.97% | -70.85% | -53.44% |
| Earnings from Continuing Operations | 15.61% | 13.82% | 2.81% | 19.54% | 8.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.61% | 13.82% | 2.81% | 19.54% | 8.06% |
| EBIT | 22.04% | 20.50% | 10.36% | 4.01% | -14.59% |
| EBITDA | 21.92% | 20.34% | 10.23% | 3.90% | -14.71% |
| EPS Basic | 21.30% | 17.61% | 5.14% | 21.97% | 38.70% |
| Normalized Basic EPS | 23.23% | 19.46% | 7.15% | 1.56% | 26.68% |
| EPS Diluted | 21.30% | 17.61% | 5.14% | 21.97% | 38.70% |
| Normalized Diluted EPS | 23.23% | 19.46% | 7.15% | 1.56% | 26.68% |
| Average Basic Shares Outstanding | 8.03% | 4.82% | 2.51% | 2.64% | 24.64% |
| Average Diluted Shares Outstanding | 8.03% | 4.82% | 2.51% | 2.64% | 24.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |